Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin

Haematologica

Volumn 98, Issue 3, 2013, Pages 455-463

  Nekhai, Sergei ^a   Xu, Min ^a   Foster, Altreisha ^a   Kasvosve, Ishmael ^b   Diaz, Sharmin ^a   Machado, Roberto F ^c   Castro, Oswaldo L ^a   Kato, Gregory J ^d   Taylor VI, James G ^d   Gordeuk, Victor R ^a,c  

^a HOWARD UNIVERSITY   (United States)

^b UNIVERSITY OF BOTSWANA   (Botswana)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENHANCED GREEN FLUORESCENT PROTEIN; FERRITIN; FERROPORTIN; HEPCIDIN; IRON; MYC PROTEIN; TRANSFERRIN; CATION TRANSPORT PROTEIN; HYBRID PROTEIN; METAL TRANSPORTING PROTEIN 1; MUTANT PROTEIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FLUORESCENCE ANALYSIS; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IRON METABOLISM; LUNG ARTERY PRESSURE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MUTANT; MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; TRICUSPID VALVE REGURGITATION; WESTERN BLOTTING; ANEMIA, SICKLE CELL; BLACK PERSON; CELL LINE; CHEMISTRY; GENE EXPRESSION; GENETICS; GENOTYPE; METABOLISM; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CATION TRANSPORT PROTEINS; CELL LINE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HEPCIDINS; HUMANS; IRON; MACROPHAGES; MUTANT PROTEINS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS;

EID: 84874537127     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066530     Document Type: Article

References (68)

1. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000;5(2):299-309.
2. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403(6771):776-81.
3. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275(26):19906-12.
4. Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, Land W, et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood brain barrier. Brain Res. 2004;1001(1-2):108-17.
5. Khan ZA, Farhangkhoee H, Barbin YP, Adams PC, Chakrabarti S. Glucose-induced regulation of novel iron transporters in vascular endothelial cell dysfunction. Free Radic Res. 2005;39(11):1203-10.
6. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106(12):3979-84.
7. Knutson MD, Vafa MR, Haile DJ, Wessling Resnick M. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood. 2003;102(12):4191-7.
8. Chung J, Haile DJ, Wessling-Resnick M. Copper-induced ferroportin-1 expression in J774 macrophages is associated with increased iron efflux. Proc Natl Acad Sci USA. 2004;101(9):2700-5.
9. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323-42.
10. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111(4): 2392-9.
11. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393-408, e1-2.
12. Grebenchtchikov N, Geurts-Moespot AJ, Kroot JJ, den Heijer M, Tjalsma H, Swinkels DW, et al. High-sensitive radioimmunoassay for human serum hepcidin. Br J Haematol. 2009;146(3):317-25.
13. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, et al. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem. 2009;389(2): 124-9.
14. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci. 2009;66(3):150-7.
15. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-7.
16. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis. 2003;31(3):299-304.
17. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis. 2003;31(3):305-9.
18. McNamara L, Gordeuk VR, MacPhail AP. Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol. 2005;20(12):1855-8.
19. Kasvosve I, Gomo ZA, Nathoo KJ, Matibe P, Mudenge B, Loyevsky M, et al. Effect of ferroportin Q248H polymorphism on iron status in African children. Am J Clin Nutr. 2005;82(5):1102-6.
20. Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007;38(3):247-52.
21. Masaisa F, Breman C, Gahutu JB, Mukiibi J, Delanghe J, Philippe J. Ferroportin (SLC40A1) Q248H mutation is associated with lower circulating serum hepcidin levels in Rwandese HIV-positive women. Ann Hematol. 2012;91(6):911-6.
22. Albuquerque D, Manco L, Loua KM, Arez AP, Trovoada Mde J, Relvas L, et al. SLC40A1 Q248H allele frequencies and associated SLC40A1 haplotypes in three West African population samples. Ann Hum Biol. 2011;38(3):378-81.
23. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106 (3):1092-7.
24. McGregor JA, Shayeghi M, Vulpe CD, Anderson GJ, Pietrangelo A, Simpson RJ, et al. Impaired iron transport activity of ferroportin 1 in hereditary iron overload. J Membr Biol. 2005;206(1):3-7.
25. Kasvosve I, Debebe Z, Nekhai S, Gordeuk VR. Ferroportin (SLC40A1) Q248H mutation is associated with lower circulating plasma tumor necrosis factor-alpha and macrophage migration inhibitory factor concentrations in African children. Clin Chim Acta. 2010;411(17-18):1248-52.
26. Glusman G, Caballero J, Mauldin DE, Hood L, Roach JC. Kaviar: an accessible system for testing SNV novelty. Bioinformatics. 2011;27(22):3216-7.
27. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-4.
28. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30(17):3894-900.
29. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-95.
30. Kato GJ, McGowan V, Machado RF, Little JA, Taylor JT, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-85.
31. Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310-8.
32. Taylor JG 6th, Ackah D, Cobb C, Orr N, Percy MJ, Sachdev V, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol. 2008;83(1):6-14.
33. Anthi A, Machado RF, Jison ML, Taveira, Dasilva AM, Rubin LJ, Hunter L, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-9.
34. Xu M, Kashanchi F, Foster A, Rotimi J, Turner W, Gordeuk VR, et al. Hepcidin induces HIV-1 transcription inhibited by ferroportin. Retrovirology. 2010;7:104.
35. De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, et al. The molecular mechanism of hepcidin mediated ferroportin down-regulation. Mol Biol Cell. 2007;18(7):2569-78.
36. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254-6.
37. Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis. 2005;35(1):33-46.
38. Qiao B, Sugianto P, Fung E, Del-Castillo, Rueda A, Moran-Jimenez MJ, Ganz T, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012;15(6):918-24.
39. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3.
40. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-44.
41. Cazzola M, Pootrakul P, Huebers HA, Eng M, Eschbach J, Finch CA. Erythroid marrow function in anemic patients. Blood. 1987;69(1):296-301.
42. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007;48(1):57-63.
43. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomaldominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001;108 (4):619-23.
44. Del-Castillo-Rueda A, Moreno-Carralero MI, Alvarez-Sala-Walther LA, CuadradoGrande N, Enriquez-de-Salamanca R, Mendez M, et al. Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man. Eur J Haematol. 2011;86(3):260-4.
45. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron Metabolism in Man. Oxford: Blackwell Scientific Publications, 1979.
46. Bensinger TA, Gillette PN. Hemolysis in sickle cell disease. Arch Intern Med. 1974;133(4):624-31.
47. Bolarinwa RA, Akinlade KS, Kuti MA, Olawale OO, Akinola NO. Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transpl. 2012;23(1):171-5.
48. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47.
49. Kato GJ, Hsieh M, Machado R, Taylor Jt, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006;81(7):503-10.
50. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
51. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-9.
52. Sachdev V, Machado RF, Shizukuda Y, Rao YN, Sidenko S, Ernst I, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49(4):472-9.
53. Ahmed Q, Chung-Park M, Tomashefski JF, Jr. Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome. Hum Pathol. 1997;28(3):264-9.
54. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal probrain natriuretic peptide concentrations. Haematologica. 2007;92(6):738-43.
55. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44-53.
56. Fonseca GH, Souza R, Salemi VC, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. Eur Respir J. 2012;39(1): 112-8.
57. Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2495-501.
58. Yang F, Wang X, Haile DJ, Piantadosi CA, Ghio AJ. Iron increases expression of ironexport protein MTP1 in lung cells. Am J Physiol Lung Cell Mol Physiol. 2002;283 (5):L932-9.
59. Qiao B, Sugianto P, Fung E, del-Castillo, Rueda A, Moran-Jimenez M-J, Ganz T, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012;15(6):918-24.
60. Girelli D, De Domenico I, Bozzini C, Campostrini N, Busti F, Castagna A, et al. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations. J Hepatol. 2008;49(4):664-71.
61. Fernandes A, Preza GC, Phung Y, De Domenico I, Kaplan J, Ganz T, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009;114 (2):437-43.
62. Barton JC, Acton RT, Rivers CA, Bertoli LF, Gelbart T, West C, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis. 2003;31(3):310-9.
63. Cremonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol. 2005;131(5):663-70.
64. Lok CY, Merryweather-Clarke AT, Viprakasit V, Chinthammitr Y, Srichairatanakool S, Limwongse C, et al. Iron overload in the Asian community. Blood. 2009;114(1):20-5.
65. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis. 2005;34(2):157-61.
66. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loreal O, Fergelot P, Delacour T, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol. 2003;39(2):286-9.
67. Lee PL, Gaasterland T, Barton JC. Mild iron overload in an African American man with SLC40A1 D270V. Acta Haematol. 2012; 128(1):28-32.
68. Zaahl MG, Merryweather-Clarke AT, Kotze MJ, van der Merwe S, Warnich L, Robson KJ. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet. 2004;115(5):409-17.